Within the immune system, interleukin-15 (IL-15) plays a relevant role by boosting the number of cytotoxic T cells and NK cells, the major drivers of anticancer immune response. Researchers from Sotio ...

Tislelizumab is BeiGene’s programmed cell death protein 1 (PD-1) checkpoint inhibitor and Anktiva is an interleukin-15 (IL-15) superagonist from ImmunityBio. The trial aims to confirm the safety ...

ImmunityBio explained that the Phase III trial design is based on the synergistic potential already demonstrated in the QUILT 3.055 study that a CPI and Anktiva, a interleukin (IL)-15 superagonist, ...

The company’s lead candidate, BMB-101, is a 5-HT2C receptor superagonist designed to address disorders like refractory epilepsy and certain neuropsychiatric conditions. The selective targeting of this ...

The MHRA has accepted the marketing authorization application for Anktiva combined with BCG for BCG-unresponsive NMIBC with CIS in the UK. Anktiva received FDA approval in the US in April 2024, and ...

EMA's acceptance of Anktiva's application marks a significant step for NMIBC treatment in Europe, following FDA approval in the US. The QUILT 3.032 trial showed a 71% complete response rate for ...

to target a specific antigen on tumor cell surface. NK cells can be activated by cytokines and cytokine fusion proteins such as IL-2, IL-15, IL-12, IL-18, IL-21, ALT-803 (an IL-15 superagonist), ...